Servier Australia

Company snapshot

Servier Australia is part of an independent international pharmaceutical group governed by a foundation. Free from share-holder interests, independence shapes how we operate, with a long-term vision focused on patients and therapeutic progress. With this unique governance model, the Group is committed to bringing new treatments to patients and integrating patients at all stages of the medicine’s l

• 6 approved product(s) across US/EU regulatory metadata.
• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Servier Australia. Not investment advice.

• approval May 29, 2026

  GSK and Alfasigma Licensing Agreement, Servier's $2.5B Acquisition

• deal Jun 2, 2026

  Servier Acquires Edgewise Therapeutics' Muscular Dystrophy Assets in Potential $2.7 Billion Deal

• What is Servier Australia?

  Servier Laboratories (Aust.) is a pharma organization headquartered in AU. Primary therapeutic focus areas include Chronic Lymphocytic Leukaemia (CLL). NovaPharmaNews links 1 clinical program(s), 7 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, Clini

• Is Servier Australia publicly traded?

  Servier Australia appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Servier Australia develop or market?

  We link 7 drug profile(s) where Servier Australia is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/servier-ireland-industries-ltd#company-drugs.

• What are the latest developments for Servier Australia?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Servier Australia focus on?

  Servier Australia focuses on Chronic Lymphocytic Leukaemia (CLL) based on our analysis of their pipeline programs and drug development activities.